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ORIGINAL ARTICLE
Peri-operative red blood cell transfusion in neonates and
infants: NEonate and children audiT of anaesthesia
pRactice IN Europe
A prospective European multicentre observational study
Alexander Fuchs, Nicola Disma, Katalin Virag, Francis Ulmer, Walid Habre, Jurgen C. de Graaff and
Thomas Riva, NECTARINE Group of the European Society of Anaesthesiology and Intensive Care
Clinical Trial NetworkM
BACKGROUND Little is known about current clinical prac-
tice concerning peri-operative red blood cell transfusion in
neonates and small infants. Guidelines suggest transfusions
based on haemoglobin thresholds ranging from 8.5 to
12 g dl1, distinguishing between children from birth to
day 7 (week 1), from day 8 to day 14 (week 2) or from
day 15 (week 3) onwards.
OBJECTIVE To observe peri-operative red blood cell trans-
fusion practice according to guidelines in relation to patient
outcome.
DESIGN A multicentre observational study.
SETTING The NEonate-Children sTudy of Anaesthesia
pRactice IN Europe (NECTARINE) trial recruited patients
up to 60 weeks’ postmenstrual age undergoing anaesthesia
for surgical or diagnostic procedures from 165 centres in 31
European countries between March 2016 and January 2017.
PATIENTS The data included 5609 patients undergoing
6542 procedures. Inclusion criteria was a peri-operative
red blood cell transfusion.
MAIN OUTCOME MEASURES The primary endpoint was
the haemoglobin level triggering a transfusion for neonates in
week 1, week 2 and week 3. Secondary endpoints were
transfusion volumes, ‘delta haemoglobin’ ( preprocedure –
transfusion-triggering) and 30-day and 90-day morbidity and
mortality.
RESULTS Peri-operative red blood cell transfusions were
recorded during 447 procedures (6.9%). The median hae-
moglobin levels triggering a transfusion were 9.6 [IQR 8.7 to
10.9] g dl1 for neonates in week 1, 9.6 [7.7 to 10.4] g dl1 in
week 2 and 8.0 [7.3 to 9.0] g dl1 in week 3. The median
transfusion volume was 17.1 [11.1 to 26.4] ml kg1 with a
median delta haemoglobin of 1.8 [0.0 to 3.6] g dl1. Thirty-
day morbidity was 47.8% with an overall mortality of 11.3%.
CONCLUSIONS Results indicate lower transfusion-trigger-
ing haemoglobin thresholds in clinical practice than sug-
gested by current guidelines. The high morbidity and
mortality of this NECTARINE sub-cohort calls for investiga-
tive action and evidence-based guidelines addressing peri-
operative red blood cell transfusions strategies.
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KEY POINTS
 Transfusion-triggering haemoglobin thresholds for
neonates and small infants in clinical practice are
lower than suggested by current guidelines.
 There is a broad variability of transfusion-triggering
haemoglobin thresholds in clinical practice.
 The described sub-cohort had a high morbidity
and mortality.
 There is an urgent need for evidence-based guide-
lines addressing peri-operative red blood cell
transfusion strategies for neonates and small infants.
Introduction
Neonates and small infants undergo physiological anae-
mia during their early days of life.1,2 Pre-operative anae-
mia is associated with increased morbidity and mortality.3
Acute surgical bleeding can cause severe anaemia with or
without cardiovascular instability leading to an immedi-
ate need for red blood cell (RBC) transfusion.4 Massive
transfusions of blood products exceeding 40 ml kg1
administered within the first 24 h post trauma, are iden-
tified as a high risk factor for early in-hospital death
among critically injured children.5 Potentially adverse
events of RBC transfusions can be classified as infectious
(bacterial, viral, parasitical or prion) or noninfectious
risks.6,7 Infectious risks are considered to be extremely
low in developed countries.7 Noninfectious risks include
haemolytic transfusion reactions, acute volume, electro-
lyte and metabolic imbalances (e.g. transfusion associated
circulatory overload) and immunomodulation (e.g. graft-
versus-host disease; transfusion-related acute lung injury
and alloimmunisation). Especially among premature
infants, RBC transfusion may be associated with intra-
ventricular haemorrhage, transfusion-associated necrotis-
ing enterocolitis, iron overload and retinopathy of
prematurity.8 Furthermore, chronic anaemia in prema-
ture infants can have potential impact on delayed weight
gain, impaired neurodevelopment and apnoea.1,9,10 Cur-
rently, there is no international consensus addressing
peri-operative Hb transfusion thresholds for neonates
and small infants. National patient blood management
guidelines focusing on critically ill neonates – perhaps the
best comparable cohort – suggest different Hb transfu-
sion-triggering thresholds for neonates for their first,
second week of life and from their third week of
life.11–13 The rationale behind this classification is based
on the consideration that neonates undergo physiological
anaemia during the first few weeks of life. Preterm infants
are especially prone to develop anaemia of prematurity.1,2
Considering the risks associated with RBC transfusion
and in an effort to reduce transfusion-related morbidity
and mortality, a clinically appropriate patient-based
approach should be enforced in this vulnerable popula-
tion.14–16
The recently published prospective cohort study, NEo-
nate-Children sTudy of Anaesthesia pRactice IN Europe
(NECTARINE),17–20 collected acute critical events and
related interventions occurring peri-operatively among
neonates and infants younger than 60 weeks postmenstr-
ual age (PMA).17 The main critical events, low haemo-
globin (Hb) levels and cardiovascular instability as
judged by the anaesthesiologist in charge, constituted
two of the primary endpoints, having resulted in an RBC
transfusion requirement caused by the intervention con-
cerned.18 Existing data revealed an overall prevalence for
a peri-operative RBC transfusion in this cohort of 6.9%
and was associated with an increased risk for morbidity,
RR 2.41 (95% CI 2.055 to 2.817), and mortality, RR 4.52
(95% CI 3.087 to 6.61).
Previous studies have focused mainly on children with a
wide range of ages. There is a paucity of data pertaining
to peri-operative RBC transfusion practice among neo-
nates and small infants. This study seeks to characterise
current peri-operative Hb transfusion-triggering thresh-
olds, to compare these findings to patient blood manage-
ment guidelines, and lastly to describe RBC transfusion
associated outcomes in this large European cohort.
Materials and methods
Study design
Detailed study design and data collection for the NEC-
TARINE cohort have been described previously.17,18 In
brief, NECTARINE is a European multicentre, prospec-
tive, observational cohort study funded by the European
Society of Anaesthesiology and Intensive Care (ESAIC)
through the Clinical Trial Network grant. Peri-operative
anaesthesia management data on children aged from
birth to 60 weeks PMA was collected in 165 European
centres. The ESAIC selected participating centres
through a ‘call for centre’. Each country was represented
by a national co-ordinator, and all participating centres
obtained ethical approval in accordance with local or
national requirements (approval forms available online:
https://www.esaic.org/research/clinical-trial-network/
completed-trials/nectarine/). Following ethics approval of
all participating centres, patients were recruited over a 3-
month period at each centre, with overall recruitment
between 1 March 2016 and 31 January 2017. The study
was registered (ClinicalTrials.gov, NCT02350348). This
manuscript adheres to the applicable Strengthening the
Reporting of Observational Studies in Epidemiology
(STROBE) guidelines (www.strobe-statement.org).
Participants
All neonates and infants up to 60 weeks of age PMA
undergoing anaesthesia for surgical or nonsurgical proce-
dures, in the operating room, paediatric or neonatal ICU
2 Fuchs et al.
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or diagnostic suite were eligible for inclusion. In the
present cohort, all patients receiving peri-operative
RBC transfusion were included.
Variables
Children were observed for the occurrence of any peri-
operative medical interventions triggered by a predefined
list of critical events. In summary, these critical events
included difficult airway management, poor peripheral
oxygen saturation (SpO2) and/or arterial oxygen satura-
tion (SaO2), end-tidal carbon dioxide (ETCO2) and/or
arterial or venous CO2 derangement, hypo or hypergly-
caemia, and/or hypo or hypernatraemia, cardiovascular
instability, hypo or hyperthermia, impaired brain oxygen-
ation as measured by near-infrared spectroscopy (NIRS)
and low Hb levels as judged by the anaesthesiologist in
charge.17,18 For each procedure, more than one critical
event could be recorded. In the critical event, ‘low Hb
level’ and/or ‘cardiovascular instability’, the selected
specific intervention could be RBC transfusion. The
transfusion-triggering Hb threshold and the RBC trans-
fusion volume were recorded. As per the NECTARINE
protocol, previous neonatal medical history, cyanotic
congenital heart defects and pre-operative physical sta-
tus including American Society of Anaesthesiology Phys-
ical Status (ASA) at the time of anaesthesia were also
documented. All the children included were followed up
30 days after the procedure for morbidity and mortality.
Morbidity considered cardiovascular, respiratory, central
nervous or surgical complications, renal impairment and
liver failure. A patient might accumulate multiple mor-
bidity complications. A second follow-up 90 days after
the procedure for in- and out-of-hospital mortality was
also conducted. Detailed definitions pertaining to
patient demography, medical history and general anaes-
thesia related parameters are contained in the study
protocol.17
Outcomes
To compare these findings to existing patient blood
management guidelines, the primary endpoint was
defined as the transfusion-triggering Hb thresholds levels
in grams per decilitre (g dl1) for children in the first week
of life (‘Group 1’), the second week of life (‘Group 2’) and
the third week of life (‘Group 3’). Secondary endpoints
were the RBC transfusion volume in millilitres per kilo-
gram body weight (ml kg1), ‘delta-Haemoglobin (DHb)
(median preprocedure Hb – median transfusion triggering Hb)
in g dl1, relationship between PMA and transfusion
trigger and 30-day and 90-day morbidity and mortality
of those children transfused.
Statistical methods
The study size determination for NECTARINE was
based on the estimation of approximately 5000 patients
in order to obtain 462 critical events, assuming that the
expected percentage of severe peri-operative critical
events is approximately 11% and the drop-out rate is
15%. An a priori statistical analysis plan for the primary
and secondary analysis was defined in the initial protocol
which is accessible online.17
Continuous variables are summarised as medians with their
first and third quartiles (Q1 and Q3, respectively), while
absolute frequencies and percentages are presented for
categorical variables.
Statistical analyses were performed using R v4.0.5. [R
Core Team (2021); R: A language and environment for
statistical computing. R Foundation for Statistical Com-
puting, Vienna, Austria] with the ‘tidyverse’ and the stats
packages.21 Ordinary least squares regression lines were
fitted to model the relationship between transfusion-
triggering Hb and PMA. We performed a receiver oper-
ating characteristic analysis to find a threshold for trans-
fusion volume (ml kg1) above which the probability of




Peri-anaesthetic data included 5609 patients undergoing
6542 procedures, between 1 March 2016 and 31 January
2017, in the 165 centres of the NECTARINE network.
At least one intervention for a critical event was recorded
in 2306 of 6437 procedures, yielding 447 RBC transfu-
sions in 406 patients (6.9%, 95% CI 6.3 to 7.6). Medical
conditions warranting RBC transfusion were listed as
follows: In 218 procedures, intra-operative anaemia was
the sole reason leading to RBC transfusion, in 113 pro-
cedures RBC transfusion was solely due to cardiovascular
instability and in 116 procedures based on both intra-
operative anaemia and cardiovascular instability. Figure 1
displays the flow-chart of the patients included and
analysed (Fig. 1).
The median age in days [first to third quartile] of the
included children at the time of transfusion was 33.0
[9.0 to 79.0] days, while the median PMA was 40.0 [37.0
to 47.0] weeks. One hundred and six patients (23.7%)
were younger than 37 weeks PMA at the time of inclusion
and 213 (47.7%) were born prematurely. The cohort had a
slight male predominance (57.5%, n¼ 257). A majority of
the patients were classified as ASA at least 3 (80.3%,
n¼ 359). When stratified according to type of procedure,
RBC transfusions occurred in 66.2% during noncardiac
surgery (52.3% during visceral surgery and 10.2% during
neurosurgery) and in 30.4% during cardiac surgery. RBC
transfusions were carried out for nonsurgical procedures
during noncardiac catheterisation in 2.0%, and during
cardiac catheterisation in 1.3% of the interventions.
The sub-cohort of transfused children contained 30 with
cyanotic congenital heart defects (7.4%), who underwent
54 procedures (12.1%). Table 1 summarises patient
NECTARINE red blood cell 3
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demography, transfusion-related data, type of procedures
and other critical events for the 447 procedures with RBC
transfusion (Table 1).
Primary endpoint
Figure 2 depicts the distribution of Hb transfusion-trig-
gering thresholds for the entire cohort. The transfusion-
triggering Hb thresholds, displayed as median [first to third
quartile], for neonates was 9.6 [8.7 to 10.9] g dl1 in group
1, 9.6 [7.7 to 10.4] g dl1 and 8.0 [7.3 to 9.0] g dl1 for
groups 2 and 3, respectively. Figure 3 displays the Hb
transfusion-triggering histogram for the three different
age groups. A weak and nonsignificant correlation was
found between transfusion-triggering Hb levels and
PMA for the three different groups (r¼ 0.27, 0.16 and
-0.18 for the first, second and as of their third week,
respectively).
Secondary endpoints
The median preprocedure Hb level was 13.9 [12.0 to
16.0] g dl1 and the DHb level was 2.4 [0.8 to 5.3] for
patients in group 1 (18.8%), which was higher than the
other two groups. The median transfusion volume was
16.7 [12.8 to 21.5] ml kg1 being lowest in the first group.
Group 2 was the smallest group in the cohort (11.6%).
This group had a median preprocedure Hb level of 12.6
[10.6 to 14.6] g dl1 and a DHb level of 1.3 [0.1 to 4.2].
The lowest DHb was also found in group 2, yielding a
median transfusion volume of 20.0 [12.5 to 30.2] ml kg1,
higher than in both of the two other groups.
Finally, group 3 was the largest of the cohort (69.6%).
The group’s median preprocedure Hb was 10.4 [9.1 to
11.8] with a median DHb of 1.6 [0.0 to 3.2] g dl1. The
preprocedure Hb was lower than the two other groups.
The median transfusion volume in this group was 17.1
[10.9 to 26.4] ml kg1.
Follow-up
Table 2 summarises the 30-day and 90-day follow-up
data. The overall 30-day complication rate was 47.8%
4 Fuchs et al.
Fig. 1 Flow-chart of included/analysed patients.
165 participating centres in 31 countries




No Red Blood Cell transfusion: 
1755 procedures
Missing value: 104 Red Blood Cell transfusion recorded in 
447 procedures due to anaemia and/or 
cardiovascular instability
Medical intervention/treatment was performed
in response to a critical event in 2306 procedures
Included for analysis
Red Blood Cell transfusion in 447
procedures (406 patients, 111 
participating centres, 28 countries)
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(194/406), representing an incidence of 51.2% (95% CI
46.0 to 56.3).
The overall mortality rate for children receiving RBC
transfusions was 11.3% (46/332), representing an inci-
dence of 13.9% (95% CI 10.3 to 18.0).
The highest complication rate and mortality was
observed in group 2, that is among children that were
transfused during their second week of life. A receiver
operating characteristic analysis was unable to identify a
threshold for transfusion volume (ml kg1) influencing
morbidity and mortality.
Discussion
The current sub-analysis of peri-operative RBC transfu-
sions among neonates and small infants of the NECTAR-
INE cohort, a prospective European multicentre
observational study, revealed a large variability for trans-
fusion-triggering Hb thresholds. Hb transfusion thresh-
olds were lower than current guidelines recommend.
Furthermore, patients exposed to peri-operative RBC
transfusions in this analysis had an almost four-fold
increased morbidity and an up to five-fold increased
mortality compared with patients who were not exposed
to RBC transfusions.
Currently, there is no international consensus regarding
peri-operative Hb transfusion thresholds for neonates and
small infants and a general paucity of tangible recom-
mendations. Existing patient blood management guide-
lines focussing on critically ill neonates, perhaps the best
comparable cohort, suggest RBC transfusion thresholds
to be based on a patient’s age. Recommendations for
transfusion-triggering Hb thresholds during the first
week of life (group 1) range between Hb 10.0 and
13.0 g dl1, between Hb 9.5 and 12.5 g dl1 during second
week of life (group 2) and between Hb 8.5 and 11.0 g dl1
from their third week of life (group 3).11–13 The rationale
behind this classification is based on the consideration
that after birth neonates undergo physiological anaemia
during the first few weeks of life. Preterm infants are
especially prone to develop anaemia of prematurity.1,2
Surprisingly, the transfusion triggers in this analysis were
found to be lower than suggested by the existing guide-
lines.11–13 A survey published in 2018 addressing current
clinical practice in Germany emphasises this existing
discrepancy.22 A 2011 Cochrane review analysed four
NECTARINE red blood cell 5
Table 1 Number of peri-operative red blood cell transfusion, demography, transfusion-related data, type of procedure and critical events
Variables Week 1 ‘Group 1’ n U 84 Week 2 ‘Group 2’ n U 52 Week >
–
3 ‘Group 3’ n U 311 Total cohort n U 447
Gestational age at birth, weeks 37.0 [34.0 to 39.0] 37.0 [28.0 to 39.0] 37.0 [30.0 to 39.0] 37.0 [31.0 to 39.0]
Birth weight, kg 2.9 [2.2 to 3.5] 2.8 [1.0 to 3.2] 2.7 [1.3 to 3.2] 2.8 [1.4 to 3.3]
Age on day of transfusion, days 3 [1 to 5] 9 [8 to 11] 61 [30 to 98] 33 [19 to 79]
Weight on day of transfusion, kg 2.9 [2.2 to 3.5] 2.8 [0.9 to 3.3] 3.6 [2.6 to 4.6] 3.2 [2.3 to 4.2]
Sex, male 54 (64.3) 28 (53.8) 175 (56.3) 257 (57.5)
ASA physical status 3 73 (86.9) 48 (92.4) 238 (76.5) 359 (80.3)
Cyanotic congenital heart defect 10 (11.9) 10 (19.2) 34 (10.9) 54 (12.1)
RBC transfusion related dataa
Preprocedure Hb, g dl1 13.9 [12.0 to 16.0] 12.6 [10.6 to 14.6] 10.4 [9.1 to 11.8] 11.1 [9.5 to 12.9]
Transfusion-triggering Hb, g dl1 9.6 [8.7 to 10.9] 9.6 [7.7 to 10.4] 8.0 [7.3 to 9.0] 8.4 [7.5 to 9.6]
RBC transfusion volume, ml kg1 16.7 [12.8 to 21.5] 20.0 [12.5 to 30.2] 17.1 [10.9 to 26.4] 17.1 [11.1 to 26.4]
Delta Hb, g dl1 2.4 [0.8 to 5.3] 1.3 [0.1 to 4.2] 1.6 [0.0 to 3.2] 1.8 [0.0 to 3.6]
Prevalence for RBC transfusion 84/817 (10.3) 52/374 (13.9) 311/5246 (5.9) 447/6437 (6.9)
Type of procedure
Surgical, noncardiacd 63 (75.0) 28 (46.2) 205 (65.9) 296 (66.2)
Gastrointestinal surgery 48 (57.1) 25 (48.1) 153 (51.7) 226 (52.3)
Neurosurgery 9 (10.7) 2 (3.8) 33 (11.1) 44 (10.2)
Thoracic surgery 1 (1.2) 1 (1.9) 9 (3.0) 11 (2.5)
Other surgerye 5 (6.0) 1 (1.9) 13 (4.4) 19 (4.5)
Specification missing 0 (0.0) 0 (0.0) 15 (4.8) 15 (3.4)
Surgical, cardiac 21 (25.0) 24 (53.8) 91 (29.3) 136 (30.4)
Nonsurgical, no cardiac catheterisation 0 (0.0) 0 (0.0) 9 (2.9) 9 (2.0)
Nonsurgical, cardiac catheterisation 0 (0.0) 0 (0.0) 6 (1.9) 6 (1.3)
Critical event for interventionc
Cardiovascular instability 76 (90.5) 43 (82.7) 216 (69.5) 335 (74.9)
Impaired oxygenation 22 (26.2) 20 (38.5) 79 (25.4) 121 (27.1)
Hypo or hypercapnia 21 (25.0) 10 (19.2) 76 (24.4) 107 (23.9)
Body temperature 21 (25.0) 16 (30.8) 55 (17.7) 92 (20.6)
Impaired brain oxygenationb 18 (21.4) 14 (26.9) 47 (15.1) 79 (17.7)
Metabolic disturbance 16 (19.0) 6 (11.5) 48 (15.4) 70 (15.7)
Difficult airway management 3 (3.6) 2 (3.8) 19 (6.1) 24 (5.4)
Values are numbers (%) for categorical or median [IQR] for continuous variables. ASA, American Society of Anesthesiology; Hb, haemoglobin; RBC, red blood cell.
a Numbers of missing data: Preprocedure Hb n¼11 (2.5%), Transfusion-triggering Hb n¼122 (27.3%), Delta Hb n¼128 (28.6%).A child might have had multiple
procedures at different times. b Near-infrared spectroscopy (NIRS) not available in 47.2% of total cases. c Multiple events for interventions were recorded during one
procedure. d One procedure could contain different types of surgery. e Including procedures for genitourinary, orthopaedic, ear nose throat, dermatology and
ophthalmology surgery.
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randomised controlled studies comparing low versus high
Hb thresholds in very premature infants requiring high
levels of respiratory support. No differences were found
in morbidity and mortality between patients subjected to
low versus high Hb thresholds. Low Hb thresholds were
defined as a Hb level of less than 11.5 g dl1 during the
first week, less than 10.0 g dl1 for the second week and
less than 8.5 g dl1 as of the third week of life.23 The
interpretation of these findings should be approached
with caution, as the studies mentioned analysed neonatal
ICU populations with birth weight 1500 g or less, or
infants 32 weeks or less gestational age and were not
6 Fuchs et al.
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Fig. 3 Regression line of the transfusion-triggering haemoglobin (Hb) in g dl1 classified by week of life in relation to postmenstrual age (weeks).
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specific to peri-operative management. The restrictive
transfusion practice did not have a significant impact on
death or major morbidities at first hospital discharge or at
follow-up. However, the review lacked conclusive clarity
relative to well tolerated lower Hb level transfusion
thresholds as well as the benefits of maintaining a higher
Hb level for the observed population. This stands in
contrast to our analysis which revealed that current Euro-
pean RBC transfusion practice for neonates and infants is
conducted at much lower Hb levels than recommended
by the above-mentioned Cochrane review.23
Red blood cell transfusion-triggering physiological
parameters
A simple and practical consideration rarely mentioned in
guidelines is that RBC transfusion is also commonly
triggered by a host of factors including clinical presenta-
tion. A patient’s Hb level is only one of many objective
laboratory parameters that can be readily obtained peri-
operatively by way of point-of-care testing such as lactate
or oxygen extraction ratio. Critical peri-operative events
including cardiovascular instability, poor global oxygen
delivery (DO2) or high oxygen consumption (VO2) need
to be recognised and treated immediately. When making
a decision whether to transfuse or not, clinicians should
consider the oxygen extraction ratio and foetal Hb pres-
ence (HbF), as HbF has a higher affinity to oxygen than
haemoglobin A. An increased VO2 to maintain peripheral
blood oxygen saturation may indicate the need for RBC
transfusion. Assessing the degree of perfusion
impairment can also be done by measuring tissue and/
or organ perfusion.24,25 Continuous real-time organ per-
fusion in neonates, especially brain and gut perfusion, is
commonly assessed with the help of noninvasive NIRS.
Unfortunately, NIRS values were not considered in this
analysis, as only half of the patients included in this
cohort had undergone anaesthesia in the presence of
NIRS monitoring. For this reason, NIRS perfusion data
did not contribute consistently to the decision to trans-
fuse. Impaired tissue oxygenation due to a decrease in
DO2 or an increase in VO2, may lead to acidaemia due to
increased lactate production. In such situations, a patient-
based approach should be promoted rather than rigidly
sticking to a number-based threshold designed to fit the
general population in question. Thus, it may be impera-
tive to transfuse some children well before the lower
limits of recommended Hb levels are reached.
A 2017 study conducted in children aged 0 to 15 years
reported peri-operative cardiovascular instability in 1.2%
of the patients with 13.2% of them requiring blood
products.26 Compared with our analysis, the documented
mortality of 5.4% of this latter study was less than half the
mortality found in our study. This underscores the find-
ing that neonates and small infants receiving peri-opera-
tive RBC transfusions are at an increased risk for
morbidity and mortality compared with older children.
Patients receiving RBC transfusions during the second
week of life showed the highest morbidity and mortality.
This finding coincided with number of properties specific
to this group when compared with the entire cohort:
Group 2 contained children with a larger portion of
NECTARINE red blood cell 7
Table 2 Morbidity, status and mortality for children with peri-operative red blood cell transfusion
Variables Week 1 ‘Group 1’ n U 78 Week 2 ‘Group 2’ n U 44 Week >
–
3 ‘Group 3’ n U 284 Total cohort n U 406
Morbidity at day 30a
Overall morbidity RBC 46 (59.0) 28 (63.6) 120 (42.3) 194 (47.8)
Cardiovascular complication 26 (56.5) 25 (89.3) 65 (54.2) 116 (59.8)
Respiratory complication 24 (52.2) 18 (64.3) 67 (55.8) 109 (56.2)
Surgical complication 20 (43.5) 9 (32.1) 57 (47.5) 86 (44.3)
Brain / CNS complication 6 (13.0) 4 (14.3) 29 (24.2) 39 (20.1)
Renal insufficiency 9 (19.6) 5 (17.9) 25 (20.8) 39 (20.1)
Liver failure 5 (10.9) 2 (7.1) 13 (10.8) 20 (10.3)
Overall morbidity NECTARINEb 132 (22.0) 81 (29.6) 495 (11.3) 708 (13.5)
Patient status at day 30
Discharged to home 29 (37.2) 16 (36.4) 143 (50.4) 188 (46.3)
Remained in hospital 18 (23.1) 4 (9.1) 48 (16.9) 70 (17.2)
Discharged to another hospital 6 (7.7.) 1 (2.3) 24 (8.5) 31 (7.6)
Remained in ICU 16 (20.5) 13 (29.5) 32 (11.3) 61 (15.0)
Missing 1 (1.3) 3 (6.8) 11 (3.9) 15 (3.7)
Patient status at day 90
Discharged to home 42 (53.8) 18 (40.9) 177 (62.6) 237 (58.4)
Still in hospital 11 (14.1) 13 (29.5) 25 (8.8) 49 (12.1)
Missing 23 (29.5) 13 (29.5) 79 (27.8) 115 (28.3)
Mortality
Overall mortality RBC 10 (12.8) 7 (15.9) 29 (10.2) 46 (11.3)
Death by day 30 8 (80) 7 (100) 26 (89.7) 41 (89.1)
Death between day 30 and day 90 2 (20) 0 (0.0) 3 (10.3) 5 (10.9)
Overall mortality NECTARINEb 16 (2.7) 15 (5.5) 72 (1.6) 103 (2.0)
Values are numbers (%). Cohort is defined as the last transfusion procedure for each child. a A child could accumulate multiple morbidity complications. b If a child had one
procedure containing RBC transfusion and an additional procedure without RBC transfusion, the follow-up data (morbidity and mortality) contribute to both groups.
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neonates with young gestational age (i.e. first quartile),
the highest proportion of ASA at least 3, the highest
proportion of cardiac surgery and received the highest
total RBC transfusion volumes. Patients with these char-
acteristics may be considered at risk for poor outcome
following RBC transfusions. The high ASA score among
patients in group 2 would indicate that these patients
were intrinsically more vulnerable and might have shown
increased morbidity and mortality irrespective of
RBC transfusions.
This study does not permit a clear indication whether the
reported mortality was a consequence of RBC transfu-
sions or if the RBC transfusions were the result of the
patients’ underlying clinical conditions and thus not
directly related to the ‘reported mortality’. Our findings
should encourage future randomised controlled trials to
investigate such questions that this study was unable to
answer. Whether the current European clinical practice
of undercutting the transfusion-triggering Hb threshold
recommendations is justified remains a point of debate.
An important finding of this study is that peri-operative
RBC transfusion is associated with increased morbidity
and mortality and should therefore be administered judi-
ciously. In the absence of impaired tissue oxygenation, a
haemodynamically stable neonate or infant is unlikely to
require RBC transfusion even when presenting with Hb
levels that are lower than the currently recommended Hb
thresholds. This point is, in part, supported by the finding
that morbidity and mortality for group 1 (neonates who
were transfused earlier in life), was not higher than group
2 (neonates who were transfused somewhat later in life),
despite group 2 having a lower DHb than group 1.
Limitations
This study has several limitations. Due to the observa-
tional design of the study, the heterogeneous distribution
and size of the groups, and the relatively small number of
patients within the groups, interpretation of these data
needs to consider the descriptive nature of several find-
ings. The current study contained also considerable
heterogeneity relative to the procedures involved, patient
demography and transfusion volumes, which may have
affected patient outcome. The data we present do not
distinguish between cardiac and noncardiac procedures
or patients with cyanotic congenital heart defects. We are
unable to report blood loss or even estimated blood loss
per procedure, as this had not been documented in the
original study data. As an approximation, we calculated
the DHb, which may also have been influenced by dilu-
tion caused by intravenous fluids administered peri-oper-
atively. Finally, Hb levels after RBC transfusion were
not recorded.
Conclusion
This study reports on RBC transfusions in neonates and
infants in their early life undergoing anaesthesia in 31
different European countries. It describes lower transfu-
sion-triggering Hb thresholds in clinical practice than
suggested by current guidelines. The question of
whether the current European clinical practice of under-
cutting the current transfusion-triggering Hb threshold
recommendations is justified remains controversial. The
considerable morbidity and mortality in this patient
population underscores the clinical relevance of this
topic. The gap between clinical practice and national
recommendations calls for urgent action on behalf of
National and Regional Societies to improve our under-
standing of safe RBC transfusion practice and patient
blood management in this vulnerable population. Best
practice guidelines should be strengthened and sup-
ported with evidence stemming from large, multicentre,
randomised controlled studies stratifying for both gesta-
tional age and selected procedures. There is an urgent
need to determine ‘age appropriate’ peri-operative trans-
fusion-triggering Hb thresholds relative to any associated
morbidity and mortality.
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